Novo Nordisk partners with OpenAI
Novo Nordisk said it will integrate OpenAI’s technology across drug discovery, manufacturing and commercial operations as part of a global partnership announced this week, signalling AI will be used beyond lab research into production and distribution functions. The company plans to upskill staff and roll the tools into research and early development first, after which broader business units will be involved, according to coverage of the deal. (reuters.com, cnbc.com)
Novo Nordisk said on April 14 it will use OpenAI tools across drug research, factories and sales operations under a new global partnership. (reuters.com) The Danish drugmaker said the rollout starts in research and early development, where staff will use artificial intelligence to analyze large datasets and spot potential drug candidates faster. The company said the program will expand to broader business units after that. (cnbc.com) Novo Nordisk said it plans to deploy OpenAI’s technology globally by the end of 2026 and pair that with workforce training to improve employees’ artificial intelligence skills. The company also said the partnership includes strict data governance and human oversight. (novonordisk.com) Drug discovery often starts with screening huge sets of biological and chemical data to find patterns a research team can test in the lab. Novo Nordisk said it wants artificial intelligence to shorten the path from that early search work to medicines reaching patients. (novonordisk.com) Novo Nordisk is making the move while competition in obesity drugs has intensified. Reuters said the company has fallen behind Eli Lilly in the weight-loss market, even as Novo remains one of the biggest makers of diabetes and obesity medicines through Wegovy and Ozempic. (reuters.com) Chief Executive Mike Doustdar said the company believes more obesity and diabetes treatments are still waiting to be discovered, and that faster development could help patients who need new options. CNBC reported that Novo framed the partnership as a way to cut the time between research and patient use. (cnbc.com) The deal also shows how drugmakers are pushing artificial intelligence beyond lab work and into manufacturing and commercial planning. Reuters reported that Novo’s agreement covers production and distribution functions, not only research. (reuters.com) Novo Nordisk announced the partnership on April 14 after posting it as April 13 news on its website, and said the first uses will begin upstream in research before moving deeper into the business. The company is betting that the same tools can help find drugs, move them through development and support delivery at scale. (novonordisk.com, novonordisk.com)
